Adage Capital Partners
CNCE

Adage Capital Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Adage Capital Partners’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-479,000
Closed -$6.68M – 769
2017
Q2 		$6.68M Sell
479,000
-21,000
-4% -$310K 0.02% 611
2017
Q1 		$8.53M Buy
500,000
+386,373
+340% +$4.63M 0.02% 560
2016
Q4 		$1.17M Buy
+113,627
New +$1.04M ﹤0.01% 661
2014
Q3 		– Sell
-510,148
Closed -$5.15M – 759
2014
Q2 		$5.15M Hold
510,148
– – 0.01% 598
2014
Q1 		$6.86M Buy
+510,148
New +$7.2M 0.02% 559

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Adage Capital Partners's CNCE Position: Q3 2017 in Review

Adage Capital Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2017, closing a stake of 479,000 shares — an estimated $6.68M sold.

Adage Capital Partners first reported a position in CNCE in Q1 2014 and held it in 5 quarters. The position peaked at $8.53M in Q1 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q3 2017.

  • Adage Capital Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Adage Capital Partners sold 479,000 Concert Pharmaceuticals, Inc. shares in Q3 2017, an estimated $6.68M.
  • Adage Capital Partners first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 5 quarters.
  • Adage Capital Partners's Concert Pharmaceuticals, Inc. position peaked at $8.53M in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2017.

Based on Adage Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.